Trial Profile
Effects of eicosapentaenoic acid on left ventricular function in patients with non-ischaemic cardiomyopathy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Chronic heart failure
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 06 Apr 2019 Status changed from recruiting to discontinued.
- 01 Jul 2014 New trial record